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ORIGINAL ARTICLE
Subfertility in Women With Rheumatoid Arthritis
and the Outcome of Fertility Assessments
JENNY BROUWER, ROSALIE FLEURBAAIJ, JOHANNA M. W. HAZES, RADBOUD J. E. M. DOLHAIN, AND
JOOP S. E. LAVEN
Objective. Subfertility is frequently encountered among female rheumatoid arthritis (RA) patients and has been asso-
ciated with disease activity and antirheumatic drugs. However, little is known about the results of the fertility
assessments in these women. Our aim was to study the outcome of fertility assessments in subfertile women with RA.
Methods. A cross-sectional study was performed in a nationwide cohort of female RA patients who were pregnant or
trying to conceive between 2002 and 2010 (Pregnancy-Induced Amelioration of Rheumatoid Arthritis Study). Patients
who had given consent for future contact (n5260) received a questionnaire on reproductive history, fertility examina-
tions, and fertility treatments. Medical files were obtained from attending gynecologists.
Results. A completed questionnaire was returned by 178 women (68%), of whom 96% had ended their efforts to con-
ceive. Eighty-two subjects (46%) had at least 1 subfertile episode, and for 61 women a diagnosis for subfertility was
available. Unexplained subfertility (48%) and anovulation (28%) were the most common gynecologic diagnoses, and
both occurred more often in RA patients than reported in the general population. Women with unexplained subfertil-
ity more often used nonsteroidal antiinflammatory drugs (NSAIDs) during the periconceptional period. Seventeen per-
cent of all pregnancies were conceived after fertility treatments. Fertility treatments had equal or higher pregnancy
rates in RA compared to other subfertile populations.
Conclusion. Unexplained subfertility is more often diagnosed in subfertile female RA patients than in the general pop-
ulation, and is related to periconceptional NSAID use. Despite the higher incidence of subfertility in women with RA,
the outcome of fertility treatments in these women appears favorable.
INTRODUCTION
Fertility is compromised in women with rheumatoid
arthritis (RA). They often have fewer children than they
intended to have and they are more often nulliparous
(1,2). In 36–42% of female RA patients diagnosed before
family completion, the time to pregnancy (TTP) exceeds
12 months (1,3), whereas in the general population, this is
only the case in 10–17% of couples (4–6). Since in most
women with RA antirheumatic treatment has to be
adjusted before they start trying to conceive, a longer TTP
can result in a prolonged period with less adequately con-
trolled disease and consequently an increased risk for per-
manent damage to the joints. Hence, understanding the
underlying mechanisms of subfertility in RA, and treat-
ment of these mechanisms whenever possible, would be
an important step forward in the care for these patients.
Fertility in a couple might be compromised by many differ-
ent factors, in the male as well as in the female partner. Male
factors for subfertility include disorders in spermatogenesis
or obstructions, causing oligospermia or azoospermia, and
ejaculatory dysfunction. Female causes include anovulation,
unilateral or bilateral tubal occlusion, and endometriosis. In
8–28% of subfertile couples, no specific cause is found dur-
ing fertility assessments. They are generally referred to as
couples with unexplained subfertility (5,7).
In most studies on fertility in RA, gynecologic data are
missing. It has been reported that pregnant women with
RA more often had a fertility treatment than pregnant
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controls (8). However, little is known on the outcome of
fertility assessments, and details on subfertility diagnoses
have not been reported.
To study the outcome of fertility assessments in women
with RA who experience subfertility, we performed a
cross-sectional study in female RA patients from the
Pregnancy-Induced Amelioration of Rheumatoid Arthritis
(PARA) cohort.
PATIENTS AND METHODS
Patients. Patients from the PARA study were invited to
participate. The PARA study was a nationwide prospec-
tive observational cohort in the Netherlands (2002–2010)
that included women with RA (1987 revised American
College of Rheumatology criteria [9]) who were trying to
conceive or were in their first trimester of pregnancy.
PARA participants had to have a good understanding of
the Dutch language and were allowed to participate more
than once. Both the PARA study and this followup study
were approved by the Erasmus MC Medical Ethical
Review Board. Of the 297 patients in the PARA cohort,
290 women gave permission to be contacted for future
research. For 30 of them no current address was known.
For comparison of the occurrence of different subfertil-
ity diagnoses in women with RA to the general popula-
tion, the incidence of these diagnoses in 2 reference
populations with subfertility are reported (5,7).
Data collection. Eligible patients received a printed
questionnaire accompanied by a postage-paid return enve-
lope. Questionnaires included inquiries on their repro-
ductive history, TTP in months and mode of conception
for each pregnancy, visits to a gynecologist, fertility
assessments, and fertility treatments.
When patients consented, data on fertility assessments
were collected from the previously attended gynecologists.
The received files and letters were checked for menstrual
cycle length, cycle irregularities and their classification
(according to the World Health Organization classifica-
tion [10]), measurements of follicle-stimulating hormone,
estrogens and progesterone, presence of ovulation, his-
tory of pelvic inflammatory disease, tests for tubal
function (hysterosalpingography, laparoscopy), presence
of endometriosis, abdominal adhesions, and sperm ana-
lysis. The diagnosis was recorded. Furthermore, data on
performed fertility treatments and their results were col-
lected. When not all required data could be extracted
from the received information, another letter was sent to
the gynecologist explicitly requesting the missing items.
In cases where the fertility examination was not reported
in full detail in the information received, we registered
the diagnostic conclusion reported by the gynecologist,
assuming the examination was performed according to
the general consensus, as described in the national
guideline by the Dutch Society for Obstetrics and Gynae-
cology (11). These guidelines describe that in all couples
consulting a gynecologist for subfertility, a fertility exam-
ination includes at least the following: excluding anovu-
lation by measuring a midluteal serum progesterone,
assessing the male’s fertility by performing a sperm analy-
sis, and establishing Fallopian tube patency either by
performing a Chlamydia antibody screening or by
performing a laparoscopy or a hysterosalpingogram.
According to the national guideline (www.nvog.nl),
unexplained subfertility was recorded when fertility
assessments did not show any plausible explanation for
the delay in the occurrence of a pregnancy (12).
RA disease characteristics were drawn from the PARA
study database (13), including date of diagnosis, presence
of rheumatoid factor or anti–citrullinated protein anti-
bodies, and disease activity scores (13). Disease activity
was scored using tender and swollen joint counts in 28
joints (DAS28), and serum C-reactive protein levels (14).
When available, the preconceptional DAS28 of the desig-
nated PARA episode was used, otherwise the first trimes-
ter DAS28 of the same episode was used (3).
Statistical analysis. To study potential selection bias,
participants and nonparticipants were compared on
obstetric history and disease characteristics as recorded
during the last PARA episode in which a subject had par-
ticipated. Intergroup differences were calculated using the
Student’s t-test and Mann-Whitney U test for continuous
outcome, and the chi-square test or Fisher’s exact test for
categorical outcome. Numbers of pregnancies, children,
and miscarriages were compared using a Mann-Whitney
U test.
The association of subfertility diagnoses with RA disease
characteristics were studied using the chi-square test,
Fisher’s exact test, or Student’s t-test. Disease activity
scores and periconceptional use of nonsteroidal anti-
inflammatory drugs (NSAIDs) and prednisone from the
first subfertile episode in the PARA study were used. A
2-sided P value less than 0.05 was considered significant.
Software used was IBM SPSS statistics, version 21, and
STATA/SE 14.1.
RESULTS
Participants. Of the 260 questionnaires sent, 178 (68%)
were completed and returned (Figure 1). Participants and
nonparticipants were compared (Table 1). Significantly
Significance & Innovations
 Subfertility in female rheumatoid arthritis (RA)
patients is most often unexplained or caused by
anovulation.
 The high percentage of RA patients, diagnosed
with unexplained subfertility by a gynecologist,
may suggest that RA-related factors are causally
involved in subfertility in women with RA.
 The diagnosis of unexplained subfertility is associ-
ated with periconceptional nonsteroidal antiinflam-
matory drug use.
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more nonparticipants had not achieved a pregnancy dur-
ing their most recent PARA study episode (37%) com-
pared to participants (17%) (P50.001). More often,
nonparticipants were nulliparous at the end of their par-
ticipation in the PARA study (24% versus 9%; P5 0.002).
There were more smokers among nonparticipants (22%)
than in participants (6.7%) (P50.001). Participants and
nonparticipants did not differ significantly regarding age,
education level, number of children they had already had,
disease characteristics, or percentage of miscarriages or
pregnancy complications.
Reproductive history. Of the participants, 170 women
(96%) had ended their efforts to establish a pregnancy.
Reasons to stop trying to conceive were (multiple answers
per subject possible): a complete family (72%), advanced
age (20%), increase of RA symptoms or the need for anti-
rheumatic drugs incompatible with pregnancy (together
19%), other health problems that complicated conception,
or taking care of a child (3%). In 9 women (5%) there were
no more fertility treatments available or their gynecologist
advised against a new pregnancy. In 3% the mental bur-
den of the wish to conceive was a reason to end their
attempts at pregnancy, and in 1% relational problems
played a role. In total, 28% ended their efforts before
they felt their family was complete. Fifty-nine women
(33%) put their efforts to conceive on hold for 1 or more
intervals, and in 32% this was due to RA symptoms or
the need for antirheumatic drugs incompatible with
pregnancy.
The participants had a total of 412 pregnancies, with a
median of 2 pregnancies (interquartile range [IQR] 2–3,
mean6SD 2.36 1.0) per woman. Of all reported pregnan-
cies, 354 pregnancies (86%) were conceived after a diag-
nosis of RA. Thirty-three percent of the women had 1 or
more miscarriages (median 0, IQR 0–1, mean6SD
0.4260.69). The total number of miscarriages was 75.
There were 334 live-born children in the study population
(median 2, IQR 1–2, mean6SD 1.96 0.78 per woman),
with a maximum of 4 children per woman. Nine women
(5%) remained nulliparous, of whom 6 (3% of partici-
pants) had never been pregnant, and 3 women (2%) had
only had pregnancies resulting in a miscarriage.
Fertility assessments. Eighty-two women (46%; 95%
confidence interval 39%–53%) were considered subfertile
because they met at least 1 of the following criteria: a TTP
exceeding 12 months during at least 1 attempt to establish
a pregnancy (n566), the use of fertility treatments to get
pregnant (n5 41), or never having achieved a pregnancy
(n56). Sixty-six women (37%) had a primary subfertility,
and 16 women (9%) experienced secondary subfertility.
The mean6SD age during the first subfertile episode was
29.463.9 years.
Subfertile women established significantly fewer preg-
nancies (2 [IQR 1–2, mean6SD 2.161.1] versus 2 [IQR
Figure 1. Flow chart of the study population and inclusion of study participants.
PARA5Pregnancy-Induced Amelioration of Rheumatoid Arthritis.
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1–3, mean6SD 2.561.0]; P5 0.004) and had fewer chil-
dren (2 [IQR 1–2, mean6SD 1.660.9] versus 2 [IQR 1–2,
mean6SD 2.160.6]; P5 0.001) than fertile women with
RA. The number of miscarriages per woman in both
groups was not significantly different (P5 0.33).
The total number of pregnancies in the subfertile
women was 168, resulting in 132 live-born children. Of
these pregnancies, 52 (31%) were conceived spontane-
ously within 12 months, 48 spontaneously conceived
pregnancies (29%) had a TTP .12 months, and 68 preg-
nancies (40%, i.e., 17% of all pregnancies) were con-
ceived with the help of fertility treatments (Figure 2).
Fertility diagnoses. Eight subfertile women (10%) had
never visited a gynecologist. Of the other 74 subfertile
women, 65 women (88%) gave permission to collect data
from their gynecologist. Data were obtained for 64 women,
of whom 61 women received a diagnosis for subfertility.
The other 3 women became pregnant spontaneously
before the fertility assessment was completed. The 61
women with a diagnosis were compared to the 21 subfer-
tile women without available diagnosis, showing no sig-
nificant differences regarding age, reproductive history, or
disease characteristics. More women without available
gynecologic files had ever used methotrexate (81% versus
54%; P5 0.030).
In the 61 women for whom a diagnosis for subfertility
was available, subfertility was most often caused by unex-
plained subfertility (48% of known diagnoses), anovula-
tion (28%), and semen abnormalities (16%) (Table 2). In 2
women (3%) anovulation was due to primary ovarian
insufficiency (POI). In 5% of the couples there was both a
female and a male cause for subfertility. For 8 of the 61
couples, the gynecologist did not report the result of a
sperm analysis. Diagnoses in these women were unex-
plained (n5 2), vaginismus (n5 1), anovulation (n5 4),
Table 1. Characteristics of participants and nonparticipants*
Participants
(n5 178)
Nonparticipants
(n5 82) P
Current age, years 40.56 4.2 40.664.3 0.834†
Missing 1 (0.6) –
Education level 0.51‡
Low 11 (6.2) 5 (6.1)
Intermediate 74 (42) 18 (22)
High 93 (52) 28 (34)
Missing – 31 (38)
At start of last PARA episode
Age during PARA, years 32.46 4.0 32.564.0 0.905†
Missing 2 (1.1) –
Previous children, median (IQR) 1 (0–1) 0 (0–1) 0.55§
Mean 0.616 0.63 0.5960.72
Missing – 1 (1.2)
Smokers 12 (6.7) 18 (22) , 0.001¶
Missing 2 (1.1) 2 (2.4)
Duration of RA, years 15.06 6.6 13.765.9 0.135†
RF positivity# 129 (72) 59 (72) 0.826¶
Missing 4 (2.2) 1 (1.2)
ACPA positivity# 114 (64) 55 (67) 0.584¶
Missing 1 (0.6) 1 (1.2)
Periconceptional DAS28# 3.76 1.2 3.561.3 0.394†
Missing 17 (9.6) 4 (4.8)
Obstetric outcome of last PARA participation
Achieved pregnancy 147 (83) 52 (63) 0.001¶
Life birth** 143 (97) 50 (96) 0.653††
Miscarriages** 4 (2.7) 1 (1.9) 1.000††
Maternal complications** 39 (27) 12 (23) 0.715††
Neonatal complications** 24 (16) 7 (13) 0.824¶
Nulliparous at end of PARA study 16 (9.0) 20 (24) 0.002††
Missing 1 (0.6) 2 (2.4)
* Values are the mean6SD or the number (percentage) unless indicated otherwise. PARA5Pregnancy-
Induced Amelioration of Rheumatoid Arthritis; IQR5 interquartile range; RA5 rheumatoid arthritis;
RF5 rheumatoid factor; ACPA5 anti–citrullinated protein antibody; DAS285Disease Activity Score in
28 joints.
† By unpaired t-test.
‡ By Fisher’s exact test on nonmissing data.
§ By Mann-Whitney U test.
¶ By chi-square test.
# At the start of the last PARA participation.
** As a percentage of achieved pregnancies during last PARA participation.
†† By Fisher’s exact test.
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and endometriosis (n51). For the 10 women for whom no
gynecology file was available, the self-reported diagnoses
were unexplained subfertility (n54), tubal factor (n52),
anovulation (n5 3, n5 1 due to POI), and endometriosis
(n5 1) (Table 2).
Of the women diagnosed by a gynecologist (n5 61),
56 (92%) had a subfertile episode in the PARA study,
of whom 27 had unexplained subfertility and 14 had
anovulation. When comparing women with unexplained
subfertility to other subfertile RA patients, there was a sig-
nificant difference in periconceptional NSAIDs use (48%
versus 17%; P50.013), which was also significant when
self-reported diagnoses were included (NSAIDs use 45%
versus 22%; P5 0.046). None of the other associations,
among which were disease activity and periconceptional
prednisone use, were significant. Women with anovulation
showed no statistically significant differences compared to
ovulatory subfertile women.
Fertility treatments. The most frequently performed
fertility treatments are summarized in Table 3. Treatments
were performed in 59 subfertile women (72%), which is
Figure 2. Overview of study participants, pregnancies, and subfertility. TTP5 time to preg-
nancy; FT5 fertility treatment.
Table 2. Fertility diagnoses in subfertile RA patients from the PARA study*
Reference population
Diagnosis
Diagnosis by
gynecologist
(n5 61)
Including
self-reported
diagnoses (n5 71)
Hull et al,
1985 (5), %
Thonneau et al,
1991 (7), %
Unexplained subfertility† 29 (48) 33 (46) 31 12
Anovulation‡ 17 (28) 20 (28) 21 32
Male factor§ 10 (16) 10 (14) 26 58
Endometriosis 4 (6.6) 5 (7.0) 6 4
Tubal occlusion§ 2 (3.3) 4 (5.6) 14 26
Vaginismus 2 (3.3) 2 (2.8) NA NA
* Values are the number (percentage) unless indicated otherwise. RA5 rheumatoid arthritis; PARA5Pregnancy-Induced
Amelioration of Rheumatoid Arthritis; NA5not applicable.
† Unexplained subfertility includes a diagnosis of cervical hostility.
‡ In 2 couples there was both anovulation and a male factor. In 2 women anovulation was due to premature ovarian
insufficiency.
§ In 2 couples there was both anovulation and a male factor. In 1 couple there was both tubal occlusion and a male factor.
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80% of the women who visited a gynecologist for subfer-
tility. In 41 women (50% of all subfertile women), fertility
treatments resulted in at least 1 pregnancy, and in 28 of
these women all conceptions were with the help of fertil-
ity treatments. Thirteen of the 20 women (65%) who
started an in vitro fertilization (IVF) treatment had had
intrauterine inseminations (IUIs) before. Treatments not
reported in the table are intravaginal insemination (1 sub-
ject), oocyte donation (1 subject), and sperm donation
(2 subjects).
DISCUSSION
This study aimed to explore the outcome of fertility
assessments in those RA patients with subfertility. We
found that subfertility in women with RA was most often
unexplained or caused by anovulation. Moreover, the
majority of subfertile RA patients received fertility
treatments, and a considerable number of all pregnancies
were conceived after women had been treated for
subfertility.
In comparison to the general population, female RA
patients appear to be more often diagnosed with unex-
plained subfertility (5,7,15,16), whereas the percentage of
subfertile women with anovulation was equal or slightly
increased compared to percentages found in the general
population (5,7,15,16). The incidence of POI appears to be
higher than in the general population (17).
The high percentage of RA patients diagnosed by the
gynecologist with unexplained subfertility may imply that
fertility in female RA patients is influenced by disease-
related factors. There was a significant association of peri-
conceptional NSAIDs use with unexplained subfertility.
This is in concordance with a previous study within the
PARA cohort where we have shown that a longer TTP was
associated with the periconceptional use of NSAIDs, also
when corrected for disease activity scores (3). In this pre-
vious study, a longer TTP was also associated with an
increase in periconceptional disease activity and the peri-
conceptional use of prednisone (3). The current results
showed neither significant differences in disease activity
nor in periconceptional prednisone use between
unexplained subfertile women and other subfertile RA
women. However, since the current study was not de-
signed to look into these associations, the numbers of
patients in these comparisons were relatively small, and
the timing of the study visit was not concurrent with the
timing of the fertility examination, these results do not
exclude disease activity or prednisone use as a cause for
subfertility in RA.
Looking further into the association of NSAIDs with
subfertility, NSAIDs have not been reported to compro-
mise embryo implantation in IVF treatments (18), but
there have been reports on NSAIDs interrupting the ovula-
tory process, possibly leading to the so-called luteinized
unruptured follicle (LUF) syndrome (19–22). In LUF syn-
drome, ovulation is inhibited without changes in men-
strual cycle length and cycle regularity and therefore
patients with LUF would probably be classified as ovula-
tory during their fertility examination. However, among
gynecologists, the existence of LUF syndrome is contro-
versial, and criteria for the existence of LUF syndrome
include a laparoscopic evaluation, with a strict timing,
which is lacking in most studies on LUF syndrome (23).
Another explanation of the relation of NSAIDs use with
unexplained subfertility may be the effect of pain on sex-
ual intercourse. The use of NSAIDs may indicate that
these women experience more pain and therefore they
might have less exposure due to a decreased frequency of
intercourse. Indeed, sexual intercourse in RA patients is
more often limited by pain or fatigue (24), but studies
specifically addressing intercourse frequency in RA
patients who try to conceive have not been performed.
Furthermore, in daily practice, RA patients who are trying
to achieve a pregnancy are often very motivated to have
regular periovulatory intercourse. However, disease activ-
ity was higher in patients who used NSAIDs versus
nonusers, suggesting that NSAIDs were taken for pain con-
trol. All patients using NSAIDs reported that this was
because of RA. No patient reported the use of NSAIDs for
other conditions.
The percentage of subfertile subjects who received fer-
tility treatments was almost 50% higher than in the gen-
eral population (4). Furthermore, the proportion of
Table 3. Fertility treatment results in female rheumatoid arthritis patients from the PARA study*
Treatments, no. Resulted in pregnancy Pregnancy rate
Treatment
Subjects
(n555)†
Sum
(range)
Missing for
no. subjects
Subjects
(n538)‡
Pregnancies
(n5 64)‡
Per
cycle, %
Per
woman, %§
IUI¶ 36 178 (1–11) 3 12 19 11 33
OI 17 77 (1–12) 3 10 15 19 59
IVF 20 42 (1–4) 1 10 17 40 50
ICSI 8 25 (1–6) – 8 15 60 100
* PARA5Pregnancy-Induced Amelioration of Rheumatoid Arthritis; IUI5 intrauterine insemination; OI5ovulation induction
(with either clomiphene citrate or follicle-stimulating hormone injections); IVF5 in vitro fertilization; ICSI5 intracytoplasmic
sperm injection.
† Eighteen women had 2 types of treatments; 4 women underwent 3 different types of treatment.
‡ One woman achieved a first pregnancy after IUI, and a second pregnancy after IVF; 1 woman conceived twice after IUI
combined with OI.
§ Percentage of women with at least 1 pregnancy (of total number of women who started treatment).
¶ In 10 women, IUI was combined with mild ovarian hyperstimulation (MOH); 9 pregnancies were after IUI with MOH.
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pregnancies that were conceived with the help of fertility
treatments conforms to earlier findings in the PARA study
(25), and is also in line with a Danish National Birth
Cohort study reporting that more pregnant RA patients
compared to pregnant controls had received a fertility
treatment (8). The pregnancy rates per treatment cycle and
per woman who started treatment were comparable to
other subfertile populations as far as IUI and ovulation
induction were concerned (26). On the contrary, the preg-
nancy rates of IVF and IVF/intracytoplasmic sperm injec-
tion (ICSI) treatments were both higher in RA women (27).
Therefore, embryo implantation does not seem to be com-
promised in RA patients. An explanation for the higher
pregnancy rate after IVF or ICSI might be explained by an
early start of fertility treatment relative to their previous
underexposure to preovulatory sexual intercourse. On the
other hand, selection bias may have occurred when
women who did not get pregnant after fertility treatments
were mainly in the nonparticipants group. However, since
data on the results of fertility treatments in these women
were scarcely available, this remains unclear.
One in 5 women had stopped trying to conceive because
of active disease or antirheumatic drugs. In the PARA
study, more than one-third of the women did not use any
antirheumatic drugs during the periconceptional period,
and less than 5% of the women used biologic agents pre-
conceptionally, whereas the disease activity was interme-
diate or high in the majority of patients (3). Over the last
decade, tumor necrosis factor inhibitors have been used
increasingly in the periconceptional treatment of women
with RA, and appear to be safe (28). Since active disease is
associated with a longer TTP (3), subfertile RA patients
may benefit from the preconceptional use of these biologic
agents, and fewer women would need to end their efforts
to build a family because of active disease.
With a higher pregnancy rate and less nulliparity than
nonparticipants, the participants in this study seemed to
be a more fertile selection of the PARA cohort. Therefore
our current results may very well be an underestimation
of the real incidence of the total subfertility and their
impact on childbearing in the total female RA population.
Since the incidence of subfertility in the PARA cohort was
consistent with other recent studies in female RA patients
of reproductive age (3), it is not likely that selection on
subfertility in the recruitment for the original PARA
cohort introduced bias in the current study and affected
our current results.
An explanation for the lower pregnancy rate and higher
nulliparity among the nonparticipants may be that they
were less desirous of achieving a pregnancy than the par-
ticipants. However, this was not the case. No differences
were found between participants and nonparticipants in
the number of children already present before the final
PARA participation. Moreover, within the nonparticipants
who did not achieve a pregnancy during the last PARA epi-
sode, more women underwent fertility treatments than the
nonpregnant participants, although this difference was
nonsignificant (data not shown). Therefore, the motivation
to achieve a pregnancy appeared not to be diminished in
the nonparticipants.
On the other hand, the cause of subfertility may have
indirectly affected patients in their choice to participate in
the current study. Fertility problems that are hard to treat,
e.g., endometriosis, or a severe oligospermia or azoosper-
mia, often have a poor treatment outcome, not leading to
the desired pregnancy. Although the patients participat-
ing in the current study did not show a higher occurrence
of these diagnoses than the general subfertile population,
the nonparticipants were more often nulliparous. There-
fore, we cannot rule out that the prevalence of these hard-
to-treat cases might be more frequent in the nonparticipant
group, and consequently also in the total RA population.
Furthermore, there were more smokers among non-
participants than among participants. This may point
toward a less healthy lifestyle, which in turn is associated
with reduced conception rates (29). Details on smoking
behavior, such as package-years, are missing in the PARA
study, and could not be analyzed further. However,
even if all the nonparticipants with a confirmed fertility
examination/fertility treatments had another diagnosis
than unexplained subfertility, the percentage of subfertile
RA patients with unexplained subfertility would still be
higher than in the subfertile part of the general population.
In conclusion, our finding that unexplained subfertility
is diagnosed more often in female RA patients than in the
general population supports the idea that RA-related
factors are causally involved in subfertility in women
with RA. Unexplained subfertility was associated with the
periconceptional use of NSAIDs. Despite the higher inci-
dence of subfertility in women with RA, the outcome of
fertility treatments in these women appears favorable. In
future research on fertility in RA, attention should also be
given to intercourse frequency and sexual problems, since
these are scarcely studied in RA patients trying to con-
ceive. In daily practice, when an RA patient wishes to
conceive, NSAIDs should be avoided, and early consulta-
tion with an expert rheumatologist and a fertility special-
ist should be considered to optimize the patient’s chance
of a complete family.
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